About
LeaderMed Group is a metabolic health and longevity company with dual divisions: a pharmaceutical arm developing GLP-1 GCGR dual agonist drugs for metabolic optimization, and UltraSculpt, a medical device division focused on non-invasive body contouring. UltraSculpt delivers targeted fat reduction and skin tightening through a single 30-minute, painless treatment using advanced ultrasonic technology. The device is FDA-cleared and works by melting away fat while simultaneously stimulating collagen production to tighten skin, with clinical studies showing waistline reductions of 3-7 cm in one session.
The company's philosophy integrates internal metabolic health with external physical transformation, positioning beauty and confidence as outcomes of optimized health rather than isolated aesthetic concerns. UltraSculpt is customizable across multiple body areas including the abdomen, thighs, arms, buttocks, neck, and chin, with adjustable intensity levels and treatment modes tailored to individual needs. The device requires zero downtime, allowing patients to return to normal activities immediately after treatment.
Longevity Contribution
- FDA-cleared Class I medical device with 7 years of R&D refinement and global patent protection
- Dual-action mechanism that simultaneously reduces fat and tightens skin in a single 30-minute session
- Clinically validated results showing 3-7 cm waistline reduction in one painless, non-invasive treatment
- Integration within LeaderMed's broader metabolic health platform combining pharmaceutical and device-based interventions